Inactive Instrument

Analyst Reco. Imago BioSciences, Inc.

Equities

Stifel Nicolaus Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35	28/22/28	MT
Jefferies Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35	22/22/22	MT
Cowen Downgrades Imago BioSciences to Market Perform From Outperform, Price Target is $36	22/22/22	MT
HC Wainwright Downgrades Imago BioSciences to Neutral From Buy, Lifts Price Target to $36 From $35	22/22/22	MT
Wedbush Downgrades Imago BioSciences to Neutral From Outperform on Heels of Announced Sale to Merck, Adjusts PT to $36 From $25	21/22/21	MT
Wedbush Starts Imago BioSciences at Outperform With $25 Price Target	28/22/28	MT
HC Wainwright Trims Imago BioSciences' Price Target to $35 From $36, Maintains Buy Rating	16/22/16	MT
HC Wainwright Adjusts Price Target on Imago BioSciences to $36 From $37, Reiterates Buy Rating	25/22/25	MT
HC Wainwright Initiates Imago BioSciences at Buy With $37 Price Target	14/22/14	MT
IMAGO BIOSCIENCES : Jefferies Starts Imago BioSciences at Buy With $30 Price Target	10/21/10	MT
IMAGO BIOSCIENCES : Guggenheim Starts Imago BioSciences at Buy With $35 Price Target	10/21/10	MT
ANALYST RECOMMENDATIONS : Berkshire Hathaway, eBay, General Electric, HSBC, Novavax...	10/21/10
IMAGO BIOSCIENCES : Cowen Initiates Coverage on Imago BioSciences With Outperform Rating	10/21/10	MT
IMAGO BIOSCIENCES : Stifel Starts Imago BioSciences at Buy With $31 Price Target	10/21/10	MT

No results for this search